Format

Send to

Choose Destination
See comment in PubMed Commons below
Can Fam Physician. 1991 May;37:1231-6.

Selegiline and the Treatment of Parkinson's Disease: How patients can benefit from drug therapy.

Abstract

Parkinson's disease involves the progressive degeneration of dopamine neurons in the extrapyramidal motor system. Levodopa, the metabolic precursor of dopamine, relieves symptoms but does not prevent continued cell death. Research suggests that monoamine oxidase B inhibitors, such as selegiline, should benefit Parkinson's patients. Evidence to date indicates that selegiline improves the effectiveness of levodopa and may even slow cell death.

PMID:
21229030
PMCID:
PMC2145357
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Support Center